Medication Formulation Preference of Mild and Moderate Ulcerative Colitis Patients: a European Survey.

Q2 Medicine Inflammatory Intestinal Diseases Pub Date : 2023-05-12 eCollection Date: 2023-06-01 DOI:10.1159/000530139
Xavier Hébuterne, Stephan R Vavricka, Helen C Thorne, Lara MacKenzie-Smith, Raphaël Laoun, Johan Burisch
{"title":"Medication Formulation Preference of Mild and Moderate Ulcerative Colitis Patients: a European Survey.","authors":"Xavier Hébuterne, Stephan R Vavricka, Helen C Thorne, Lara MacKenzie-Smith, Raphaël Laoun, Johan Burisch","doi":"10.1159/000530139","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Patient adherence is a major challenge for the successful management of any chronic disease, and ulcerative colitis (UC) is no exception. Patient adherence is closely related to patient preference of medication and formulation used.</p><p><strong>Aim: </strong>The aim of this study was to investigate patient and physician perspectives around UC treatment preference.</p><p><strong>Methods: </strong>This study was conducted in France, Germany, Spain, and the UK. Physicians and UK inflammatory bowel disease (IBD) nurses answered an online questionnaire. In addition, adult mild-to-moderate UC patients, treated with oral mesalazine, were invited to answer a 30-min online survey which included a conjoint exercise.</p><p><strong>Results: </strong>400 patients, 160 physicians, and 20 IBD nurses participated in the survey. 68% of patients were taking tablets and 32% granules. Physicians stated that from their perspective patients are more adherent to tablets than granules (76% vs. 24%), patients tended to have better relief of symptoms with tablets (69% vs. 31%), and patients found tablets to be the most convenient formulation (61% vs. 39%). From the patients' perspective, when questioned which formulation they prefer, 58% answered tablets, 37% granules, and 5% none of these. When patients were asked about some negative attributes of tablets, the highest agreement was for \"I would like to take fewer each day\" (6.1/10) and \"I wish I could take fewer at a time\" (5.4/10).</p><p><strong>Conclusions: </strong>The majority of UC patients in this survey prefer the tablet formulation. A high strength tablet overcoming the high pill burden could be a good solution to address patient expectations.</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":"8 1","pages":"41-49"},"PeriodicalIF":0.0000,"publicationDate":"2023-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10498945/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Inflammatory Intestinal Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000530139","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/6/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Patient adherence is a major challenge for the successful management of any chronic disease, and ulcerative colitis (UC) is no exception. Patient adherence is closely related to patient preference of medication and formulation used.

Aim: The aim of this study was to investigate patient and physician perspectives around UC treatment preference.

Methods: This study was conducted in France, Germany, Spain, and the UK. Physicians and UK inflammatory bowel disease (IBD) nurses answered an online questionnaire. In addition, adult mild-to-moderate UC patients, treated with oral mesalazine, were invited to answer a 30-min online survey which included a conjoint exercise.

Results: 400 patients, 160 physicians, and 20 IBD nurses participated in the survey. 68% of patients were taking tablets and 32% granules. Physicians stated that from their perspective patients are more adherent to tablets than granules (76% vs. 24%), patients tended to have better relief of symptoms with tablets (69% vs. 31%), and patients found tablets to be the most convenient formulation (61% vs. 39%). From the patients' perspective, when questioned which formulation they prefer, 58% answered tablets, 37% granules, and 5% none of these. When patients were asked about some negative attributes of tablets, the highest agreement was for "I would like to take fewer each day" (6.1/10) and "I wish I could take fewer at a time" (5.4/10).

Conclusions: The majority of UC patients in this survey prefer the tablet formulation. A high strength tablet overcoming the high pill burden could be a good solution to address patient expectations.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
轻、中度溃疡性结肠炎患者的药物配方偏好:一项欧洲调查。
引言:患者的依从性是成功治疗任何慢性病的主要挑战,溃疡性结肠炎(UC)也不例外。患者的依从性与患者对药物和所用配方的偏好密切相关。目的:本研究的目的是调查患者和医生对UC治疗偏好的看法。方法:这项研究在法国、德国、西班牙和英国进行。医生和英国炎症性肠病(IBD)护士回答了一份在线问卷。此外,还邀请接受口服美沙拉秦治疗的成年轻度至中度UC患者回答一项30分钟的在线调查,其中包括一项联合运动。结果:400名患者、160名医生和20名IBD护士参与了调查。68%的患者服用片剂,32%服用颗粒剂。医生表示,从他们的角度来看,患者对片剂的粘附性比颗粒更强(76%对24%),患者服用片剂往往能更好地缓解症状(69%对31%),患者发现片剂是最方便的配方(61%对39%)。从患者的角度来看,当被问及他们更喜欢哪种配方时,58%的人回答片剂,37%的人回答颗粒剂,5%的人没有回答。当患者被问及片剂的一些负面属性时,最高的一致意见是“我希望每天少吃”(6.1/10)和“我希望一次少吃”(5.4/10)。结论:本次调查中的大多数UC患者更喜欢片剂配方。克服高药丸负担的高强度片剂可能是解决患者期望的好方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Inflammatory Intestinal Diseases
Inflammatory Intestinal Diseases Medicine-Gastroenterology
CiteScore
4.50
自引率
0.00%
发文量
6
审稿时长
20 weeks
期刊最新文献
The Role of Esophageal Physiologic Tests in Eosinophilic Esophagitis. Real-World Effectiveness and Safety of Carotegrast Methyl in Japanese Patients with Moderately Active Ulcerative Colitis. Perceptions and Responses to Diseases among Patients with Inflammatory Bowel Disease: Text Mining Analysis of Posts on a Japanese Patient Community Website. Impact of Concomitant Prescriptions and Lifestyle Factors on the Initial Course of Newly Diagnosed Inflammatory Bowel Disease. A Real-World Comparison of Drug Trough Levels between Patients Experiencing a Secondary Nonimmune Loss of Response and Those Maintaining a Response to Infliximab on Long-Term Maintenance Therapy for Inflammatory Bowel Disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1